To further analyze the influence of low-dose peg-IFN α-2a treat regimen to SVR, we also conducted multivariate stepwise analysis included in the model the following preselected variables: peg-IFN α-2a dose of treatment, gender, age, HCV genotype, absence of cirrhosis, and HCV RNA level. This evidence concerns the gene IFNA1 and Cirrhosis.